Testing a new RET drug for advanced lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This Phase 1/2 study tests lunbotinib, a new medicine that targets a specific lung-cancer change called RET. It aims to see how well it works and how safe it is for adults with advanced RET-altered non-small cell lung cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older and have documented RET-altered non-small cell lung cancer
- You must be able to sign consent and attend study visits and tests
- Your general health is good (ECOG 0–1) and you’re expected to live more than 3 months
- Your cancer can be measured on scans (measurable disease)
- Your lung cancer is locally advanced or metastatic RET fusion and you could normally receive platinum doublet chemotherapy
- If this is your first cancer treatment for advanced disease, you must not have had a RET-targeted pill or chemotherapy before
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an “RET-inhibitor” medicine (TAS0953/HM06) for advanced solid tumors that have RET gene changes. It may help shrink tumors by blocking cancer growth signals from the RET gene.
This early-phase trial tests lunresertib alone or with other study drugs in people with advanced solid tumors that have certain tumor gene changes. It aims to see whether the treatment is safe and whether it can help shrink or control cancer.
This trial tests a combination of two medicines (pembrolizumab and lenvatinib) for people with advanced non-small cell lung cancer that has a specific RET gene change. The treatment may help slow down or shrink the cancer, and the study checks how well people tolerate it.
This study tests a combination of two drugs — pralsetinib (a targeted therapy) and leucogen (a white blood cell booster) — in people with a certain type of advanced lung cancer that has not been treated before. The genetic marker RET fusion makes the cancer likely to respond to pralsetinib, and leucogen may help prevent low white blood cell counts.
This trial tests an investigational drug, SNH-118110, for people with advanced solid tumors that have a specific genetic change called RET. It aims to see if the drug can shrink tumors or slow their growth.
This trial tests a new targeted therapy (vebreltinib plus PLB1004) against standard chemotherapy for people with advanced non-small cell lung cancer that has a specific change (EGFR mutation) and MET protein, and has stopped responding to earlier EGFR treatment.
Hear when a new NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.